Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Literature DB >> 12037093

In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.

Stefano P Bachmann¹, Thomas F Patterson, José L López-Ribot.

Abstract

Caspofungin inhibits the synthesis of 1,3-beta-D-glucan, a key step in fungal cell wall biosynthesis. Here we report on its potent in vitro activity (MIC at which 90% of the isolates tested are inhibited = 1 microg per ml of RPMI medium) against 32 Candida albicans fluconazole-susceptible and -resistant clinical isolates irrespective of the underlying resistance mechanism (alterations in ERG11 and/or upregulation of MDR and CDR genes encoding efflux pumps) and provide further evidence that caspofungin is not a substrate for multidrug transporters.

Entities: Chemical Species

Mesh：

Substances：

Year: 2002 PMID： 12037093 PMCID： PMC130826 DOI： 10.1128/JCM.40.6.2228-2230.2002

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

11 in total

1. In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species.

Authors: F Barchiesi; A M Schimizzi; A W Fothergill; G Scalise; M G Rinaldi
Journal: Eur J Clin Microbiol Infect Dis Date: 1999-04 Impact factor: 3.267

2. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis.

Authors: F M Müller; M Weig; J Peter; T J Walsh
Journal: J Antimicrob Chemother Date: 2000-08 Impact factor: 5.790

3. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene.

Authors: Dominique Sanglard; Françoise Ischer; Michel Monod; Jacques Bille
Journal: Microbiology (Reading) Date: 1997-02 Impact factor: 2.777

4. In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida isolates: influence of assay conditions.

Authors: P W Nelson; M Lozano-Chiu; J H Rex
Journal: J Med Vet Mycol Date: 1997 Jul-Aug

Review 5. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.

Authors: T C White; K A Marr; R A Bowden
Journal: Clin Microbiol Rev Date: 1998-04 Impact factor: 26.132

6. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).

Authors: K Bartizal; C J Gill; G K Abruzzo; A M Flattery; L Kong; P M Scott; J G Smith; C E Leighton; A Bouffard; J F Dropinski; J Balkovec
Journal: Antimicrob Agents Chemother Date: 1997-11 Impact factor: 5.191

7. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients.

Authors: S Perea; J L López-Ribot; W R Kirkpatrick; R K McAtee; R A Santillán; M Martínez; D Calabrese; D Sanglard; T F Patterson
Journal: Antimicrob Agents Chemother Date: 2001-10 Impact factor: 5.191

8. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors.

Authors: D Sanglard; F Ischer; M Monod; J Bille
Journal: Antimicrob Agents Chemother Date: 1996-10 Impact factor: 5.191

9. Simple method for detecting fluconazole-resistant yeasts with chromogenic agar.

Authors: T F Patterson; S G Revankar; W R Kirkpatrick; O Dib; A W Fothergill; S W Redding; D A Sutton; M G Rinaldi
Journal: J Clin Microbiol Date: 1996-07 Impact factor: 5.948

10. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.

Authors: F Marco; M A Pfaller; S A Messer; R N Jones
Journal: Diagn Microbiol Infect Dis Date: 1998-09 Impact factor: 2.803

31 in total

Review 1. [New medications for treatment of systemic mycoses].

Authors: I Schedel
Journal: Internist (Berl) Date: 2005-06 Impact factor: 0.743

2. Flow cytometry susceptibility testing for the antifungal caspofungin.

Authors: M Mitchell; M Hudspeth; A Wright
Journal: J Clin Microbiol Date: 2005-06 Impact factor: 5.948

Review 3. Epidemiology of invasive candidiasis: a persistent public health problem.

Authors: M A Pfaller; D J Diekema
Journal: Clin Microbiol Rev Date: 2007-01 Impact factor: 26.132

4. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1.

Authors: Sergey V Balashov; Steven Park; David S Perlin
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

5. Characterization of caspofungin susceptibilities by broth and agar in Candida albicans clinical isolates with characterized mechanisms of azole resistance.

Authors: Peter M Silver; Brian G Oliver; Theodore C White
Journal: Med Mycol Date: 2008-05 Impact factor: 4.076

6. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors: M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal: J Clin Microbiol Date: 2008-06-25 Impact factor: 5.948